CompletedNCT04855760
Long-term safety of REL-1017 for major depression
About this title
Read the official source — NCT04855760This study evaluated the long-term safety of REL-1017 for people with depression.
Medication studyAges 18–65United States
Understand this study
What did researchers investigate?
This study evaluated the long-term safety of REL-1017 for people with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Miami and 8 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: April 1, 2021
- Recruitment status
- Completed
- Enrollment listed in the registry
- 627
- Sponsor
- Relmada Therapeutics, Inc.
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04855760
- Official title
Show the full official title
A Phase 3, Multicenter, Open-Label Study to Assess the Long-Term Safety of REL-1017 as a Treatment of Major Depressive Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Miami · Orlando · Palm Bay
4 more locations
- Chicago
- Boston
- Watertown
- Staten Island
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the long-term safety of REL-1017 for people with depression.
Who is behind this study?
The study sponsor is Relmada Therapeutics, Inc.
Did this study involve medication?
Yes. The study involved medication, including REL-1017.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
